News

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi aiming to become the first vertically integrated psychedelics firm to formulate and trial MDMA for healthy subjectsVANCOUVER, British Columbia,…

2 years ago

Bicycle Health Announces $5 Million Investment From Cobalt Ventures to Scale Its Virtual Opioid Use Disorder Treatment

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Bicycle Health, the leading provider of virtual opioid addiction treatment, today announced an…

2 years ago

BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

Company to introduce the most advanced iteration of its signal processing technology at Cleveland Clinic’s Global EP Summit 2022, a…

2 years ago

Quad M Solutions Announces Appointment of CFO Squad to Assist with Financial Reporting and Accounting Automation

Garland, TX, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Quad M Solutions, Inc. (OTC: MMMM) a staffing company providing modern health…

2 years ago

Vericel to Present at the Ladenburg Thalmann Healthcare Conference

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…

2 years ago

SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a…

2 years ago

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology…

2 years ago

WIMI Hologram Academy: Two New Techniques for Phase Disentanglement

HONG KONG, Sept. 22, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,…

2 years ago

Albireo Announces $115 Million Royalty Monetization Agreement with Sagard

Upfront payment for continued clinical development and commercialization of Bylvay®Sagard to receive a mid-single digit average royalty rate on Bylvay…

2 years ago

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd. VANCOUVER, Sept.…

2 years ago